I'd really like to see..Theralase announce a new Phase 1. On a new indication, where they can apply the entire panoply of their ACT technology. It should be Solid Tumor study not a topical, intravesical. It should showcase not just 1433 but Rutherrin, or maybe a osmium or irridium based PDC. It should start with the TLC-2000 modified for the CLT cancer pre-treatment, then move on to IV drip, then to x-ray activation. This of course means no DFOC, so lower possibility of a Phase 1 or 2 mistake.
Then instead of follow on treatments they showcase their vaccine tech. I vote for Breast as this indication as that would get a lot of hearts pumping. ;-)